This content is machine translated AHA Scientific Sessions 2018 Dapagliflozin reduces heart failure hospitalization rate Diabetes is associated with an increased cardiovascular risk, which should be taken into account therapeutically. In 2015, the EMPA-REG OUTCOME study demonstrated positive cardiovascular effects of the SGLT-2 inhibitor empagliflozin.…